Epigenetic regulation that downregulates the expression of IFI16 has been found to inhibit the STING-CXCL10/11 signaling pathway, which can enhance the anti-tumor effect of anti-HER2 trastuzumab.532 Notably, in cervical cancer, IFI16 can upregulate PD-L1 in the immune microenvironment through the STING-TBK1-NF-kB pathway, thus promoting tumor progression. The gene discussed is ERBB2; the disease is neoplasm.